 |
11 Diseases |  |
40 Trials |
|
40 Trials |  |
2608 News |  |
| «12345678910111213...3738» |
- EFFICACY AND SAFETY OF ADVANCED MEDICAL TREATMENTS FOR INDUCTION OF REMISSION IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_4909;
There was moderate certainty of evidence for combination of ADA and azathioprine (AZA) (RR 3.1, 95%CI [2.0-4.8]; risk difference [RD]: 40.1%), IFX+AZA (RR 2.5, 95%CI [1.7-3.8]; RD: 28.9%), ADA (RR 2.5, 95%CI [1.8-3.5]; RD:28.5%), and UST (RR 2.0 95%CI, [1.6-2.5]; RD: 19.2%) in induction of clinical remission compared to placebo...Conclusion On network meta-analysis, combination of anti-TNFs and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have examples of similarly important effect sizes, but are currently limited due to the imprecision of the limited evidence base at present and future research should target these therapies in study
- Tremfya (guselkumab) / J&J
ARGES-CMES: A NOVEL, CONTINUOUS SCORING FOR ULCERATIVE COLITIS DISEASE SEVERITY: PREDICTION AND SENSITIVITY IN ASSESSING TREATMENT RESPONSE (152AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4182;
P2/3, P3
The Arges-CMES novel scoring system effectively detects significant treatment differences and demonstrates a larger effect size than MES. As a result, Arges-CMES has the potential to reduce the required sample size for a given power threshold compared to MES.
- Tremfya (guselkumab) / J&J
GUSELKUMAB IMPROVES SYMPTOMS OF FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12 (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3323;
P2/3
As a result, Arges-CMES has the potential to reduce the required sample size for a given power threshold compared to MES. Moderately to severely active UC patients who received GUS induction treatment showed greater improvement in patient-reported symptoms of fatigue at Week 12 compared with placebo-treated patients.
- Tremfya (guselkumab) / J&J
GUSELKUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY PROMIS-29 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3321;
P2/3
Moderately to severely active UC patients who received GUS induction treatment showed greater improvement in patient-reported symptoms of fatigue at Week 12 compared with placebo-treated patients. Pts with moderately to severely active UC treated with GUS IV induction experienced broad and clinically meaningful improvements in HRQoL as measured by the PROMIS-29 at Wk 12.
- PATIENTS IN TRIALS OF MODERATE-TO-SEVERE UC WHO ARE EXPOSED TO PLACEBO ARE MORE LIKELY TO SUFFER HARM THAN THOSE RECEIVING ACTIVE TREATMENT: THE LACK OF CLINICAL EQUIPOISE IN TRADITIONAL STUDY DESIGNS (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3207;
Induction treatment responders re-randomized for maintenance to PBO experienced greater harms (lower NNH) than treat-through PBO patients. These findings raise concern about clinical equipoise in PBO-controlled trials of moderate-to-severe UC and support ongoing efforts to design trials with active comparator arms and adaptive or platform methodologies.
- Tremfya (guselkumab) / J&J
GUSELKUMAB BINDING TO CD64+ IL-23 (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3199;
In in vitro assays GUS, but not RZB, showed Fc-mediated binding to CD64 on IFN?-primed monocytes. CD64-bound GUS simultaneously captured IL-23 secreted from the same cells.
- Tremfya (guselkumab) / J&J
ORAL IL-23R ANTAGONIST MINIPROTEIN MB1 IS AS EFFECTIVE AS GUSELKUMAB IN A PRECLINICAL MODEL OF COLITIS (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3189;
This work demonstrates for the first time that de novo designed miniproteins can be administered orally and reach a therapeutic target past the gut epithelial barrier. With very high potency, gut stability, and straightforward manufacturability, de novo designed minibinders are a promising new modality for orally delivered biologics.
- Tremfya (guselkumab) / J&J
GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3188;
P2/3
GUS induction restored intestinal immune homeostasis in pts with UC who achieved key endpoints at WK12, demonstrated by resolution of inflammation associated with the IL-23 pathway and inflammatory myeloid, epithelial and fibroblast transcriptional states. GUS also promoted epithelial repair as evidenced by increases in epithelial cell population, consistent with endoscopic and histologic outcomes at WK12.
- Tremfya (guselkumab) / J&J
DEVELOPMENT OF A CROHN'S DISEASE MOLECULAR ACTIVITY SCORE TO IDENTIFY REGION-SPECIFIC CHRONICALLY INFLAMED AND NON-INFLAMED PROCESSES (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3185;
P2/3
Application of the MAS to identify inflamed tissue enabled identification of key immune and inflammatory related processes across the ileum and colon that were associated with the IL-23 pathway, and baseline regional endoscopic and histologic severity. By identifying inflamed baseline samples, molecular changes associated with treatment can be more accurately defined in future analyses to better understand regional heterogeneity in CD.
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
GUSELKUMAB AND GOLIMUMAB COMBINATION INDUCTION THERAPY IN ULCERATIVE COLITIS RESULTS IN EARLY LOCAL TISSUE HEALING THAT IS SUSTAINED THROUGH GUSELKUMAB MAINTENANCE THERAPY (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3184;
P2
Correlative analysis supports the role of GUS as the primary driver of tissue healing, with GOL further contributing to innate inflammatory activity, which demonstrate differential and complementary mechanisms of action of TNF? and IL-23p19 subunit blockade.
- | Tremfya (guselkumab) / J&J
Journal, Patient reported outcomes: Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. (Pubmed Central) - Mar 13, 2024
P3
and IL-23p19 subunit blockade. In biologic-na
- || Review, Journal: Update for surgeons on novel induction treatments for acute severe inflammatory bowel disease associated colitis. (Pubmed Central) - Mar 7, 2024
A significant proportion of patients did not respond, highlighting the inherent challenge in optimizing treatment for moderate to severe IBD-associated colitis. More robust study designs and comparator trials are required.
- | Journal: Structural Basis for p19 Targeting by Anti-IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. (Pubmed Central) - Mar 6, 2024
In contrast, kon, epitope hydrophobicity, polarity, and charge content did not correlate with efficacy. These data exemplify how molecular principles of medications within a therapeutic class can explain their differential clinical responses.
- ||| Tremfya (guselkumab) / J&J
P3 data, Journal: Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Study. (Pubmed Central) - Mar 6, 2024
These data exemplify how molecular principles of medications within a therapeutic class can explain their differential clinical responses. No abstract available
- ||| Tremfya (guselkumab) / J&J
P3 data, Journal: The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study. (Pubmed Central) - Mar 6, 2024
No abstract available No abstract available
- | Tremfya (guselkumab) / J&J
Journal: Efficacy and Safety of Guselkumab in Crohn's Disease: Results From the GALAXI 1 Study. (Pubmed Central) - Mar 6, 2024
No abstract available No abstract available
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
Trial primary completion date, Combination therapy: DUET-CD: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Mar 2, 2024
P2, N=715, Recruiting, Sponsor: Janssen Research & Development, LLC
No abstract available Trial primary completion date: Jul 2024 --> May 2025
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
Trial completion date, Trial primary completion date, Combination therapy: DUET-UC: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Mar 2, 2024
P2, N=550, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jul 2024 --> May 2025 Trial completion date: Feb 2029 --> Aug 2030 | Trial primary completion date: Aug 2024 --> May 2025
- Tremfya (guselkumab) / J&J
Guselkumab showed good efficacy in treating generalized pustular psoriasis, with a low relapse rate and reduction in CD8+ tissue-resident memory T cells (Room 20B) - Mar 1, 2024 - Abstract #AAD2024AAD_3671;
- | Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Journal: Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials. (Pubmed Central) - Feb 28, 2024
Trial completion date: Feb 2029 --> Aug 2030 | Trial primary completion date: Aug 2024 --> May 2025 IPD analysis demonstrated that both guselkumab doses were superior to ustekinumab for ACR 20 from weeks 16 (biologic-na
- || Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Review, Journal: From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature. (Pubmed Central) - Feb 26, 2024
Early intervention is crucial for PsO patients at high risk of PsA; T cells, particularly type 17 helper T cells, and CD8+ cells are key in the progression from PsO-to-PsA. Early targeting of TRM in PsD shows promise but more research is needed.
- ||| Tremfya (guselkumab) / J&J
P3 data, Journal: Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis. (Pubmed Central) - Feb 22, 2024
P3
Early targeting of TRM in PsD shows promise but more research is needed. Patients with active PsA treated with guselkumab demonstrated reduced impairment in work productivity and nonwork daily activity, together with improvement in general health status and substantial potential cost savings, over a 2-year period.
- | Tremfya (guselkumab) / J&J
Journal: Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment. (Pubmed Central) - Feb 20, 2024
IRF7 may be the key player in psoriasis pathogenesis and the therapeutic process involving guselkumab. Targeting IRF7 might offer new therapeutic strategies for psoriasis.
- IL-23 inhibitors as a treatment option for pyoderma gangrenosum: a systematic review (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_3152;
Mean age was 49.5 y.o. and majority were women (71%) Inflammatory Bowel Disease history noted in 42% of patients. Lower limbs were main site of PG (54%).
- Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Tremfya (guselkumab) / J&J
The Efficacy and Safety of Switching From Different Biologics To Interleukin-23 Inhibitors: A Systematic Review () - Feb 20, 2024 - Abstract #AAD2024AAD_3020;
Adverse events during IL-23 treatment were uncommon (13%, 115/870) with the most common adverse event being infection in 8.0% (70/870) of patients. Switching to IL-23 inhibitors from other biologics generally results in favorable outcomes with minimal adverse events, supporting their potential as effective alternatives in psoriasis treatment.
- Tremfya (guselkumab) / J&J
VISIBLE: Clearance and Symptom Improvement With Guselkumab at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_3013;
Switching to IL-23 inhibitors from other biologics generally results in favorable outcomes with minimal adverse events, supporting their potential as effective alternatives in psoriasis treatment. After 3 doses of guselkumab, the majority of participants with moderate-to-severe plaque psoriasis achieved significantly clearer skin and reported clinically meaningful improvement in psoriasis symptoms.
- Tremfya (guselkumab) / J&J
Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) () - Feb 20, 2024 - Abstract #AAD2024AAD_3011;
P
After 3 doses of guselkumab, the majority of participants with moderate-to-severe plaque psoriasis achieved significantly clearer skin and reported clinically meaningful improvement in psoriasis symptoms. This descriptive analysis may help clinicians better understand the characteristics of patients with psoriasis prescribed guselkumab or an IL-17i in a real-world setting and interpret future analyses based on PSOLAR data.
- Tremfya (guselkumab) / J&J
Guselkumab for Treatment of Plaque Psoriasis: Persistence and Switching in Real-World Clinical Practices in the US () - Feb 20, 2024 - Abstract #AAD2024AAD_3004;
Results provide insights into the real-world experience of patients initiating guselkumab for treatment of PsO. Prior experience with biologic therapy and rheumatology referral appear to influence persistence and switching among guselkumab initiators.
- Skin of Color Representation in Drug Advertisements for Biologic Treatments FDA-approved for Psoriasis () - Feb 20, 2024 - Abstract #AAD2024AAD_2996;
Five of the 11 had >90% representation of skin types I-III, with two drug websites only representing skin types I-III (certolizumab, tildrakizumab). This lack of representation may be a potential barrier for SoC patients when initiating therapy, and may contribute to treatment delays and worsened severity.
- Tremfya (guselkumab) / J&J
Guselkumab improves moderate-to-severe psoriasis and patient satisfaction leading to high patient benefit in a real-life setting: Results from the G-EPOSS study through Week 76 () - Feb 20, 2024 - Abstract #AAD2024AAD_2989;
Conclusions The G-EPOSS study supports the long-term effectiveness and safety of guselkumab in psoriasis patients in real-life, routine clinical practice through W76, noting further improvements from previously reported interim results at W28. Moreover, with improvements in psoriasis, patient
- Tremfya (guselkumab) / J&J
Guselkumab induction therapy is effective, safe and long lasting in mild psoriasis patients, results from a randomized, placebo-controlled exploratory trial () - Feb 20, 2024 - Abstract #AAD2024AAD_2988;
P=N/A
Our results indicate that a short blockade of IL-23 in mild psoriasis patients does not induce disease modification, but effects in patients using other approaches such as early intervention remain to be explored. (ClinicalTrials.gov Listing: NCT04394936)
- Tremfya (guselkumab) / J&J
Guselkumab improves sexual health in patients with moderate-to-severe psoriasis, including patients across different age and weight groups: Results from the real-life G-EPOSS study until Week 76. (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2982;
The latter improved across all age groups, including patients ?60 years of age, and across all weight groups, including obese patients with a BMI >30. Overall, these results provide insight into sexual satisfaction in a real-life psoriasis population.
- Tremfya (guselkumab) / J&J
Guselkumab improves perceived stigmatization in moderate-to-severe psoriasis patients, including obese patients and patients with short disease duration: Results from the real-life G-EPOSS study until Week 76 () - Feb 20, 2024 - Abstract #AAD2024AAD_2980;
Conclusion These results show an association between disease control with guselkumab treatment and improvements in perceived stigmatization in psoriasis patients through W76. Findings were independent of BMI, and treating early after disease onset, with good clinical outcomes, led to more rapid resolution of perceived stigmatization.
- Tremfya (guselkumab) / J&J
VISIBLE: Guselkumab Provides Significant Improvements in Health-related Quality of Life in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis () - Feb 20, 2024 - Abstract #AAD2024AAD_2949;
GUS treatment significantly improved HRQoL as assessed by the PSSD and DLQI. After just 3 doses, nearly half of all participants reported no impact of PsO on their HRQoL.
- Tremfya (guselkumab) / J&J
VISIBLE: Guselkumab Demonstrates Significant Skin Clearance in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis Regardless of Baseline Inflammatory Disease Burden (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2947;
After just 3 doses, guselkumab led to significant skin clearance regardless of baseline inflammatory burden. The trend towards numerically better efficacy in participants with lower inflammatory burden supports the importance of controlling systemic inflammation in psoriasis as measured by Hs-CRP.
- Tremfya (guselkumab) / J&J
Guselkumab improves psoriatic skin and HRQoL outcomes across BMI subgroups, including patients with involvement of hard-to-treat areas: results from the real-world PERSIST study (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2945;
Conclusions Guselkumab was highly effective at achieving skin and HRQoL endpoints across all BMI subgroups, including those for hard-to-treat areas, although skin response rates tended to be greater in those with lower BMI. Nevertheless, rates in the higher BMI-subgroups continued to increase and generally approached the values of the lower BMI-subgroups by W104.
- Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO) (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2944;
The adjusted ORs (95% CIs) of achieving PASI100 (M12) for the IL-17A/RA cohort, was 1.3 (1.02,1.71), 2.0 (1.24,2.61) and 0.9 (0.77,1.14) compared to TNF-?, IL-12/23 p40, and IL-23 p19 cohorts respectively. This analysis highlighted the short- and long-term effectiveness and durability of anti-IL-17A/RA biologics compared to other biologic classes.
- Humira (adalimumab) / AbbVie
Real-World Switch Rates in Patients with Psoriasis Treated with Biologics Over 3 Years in the United States () - Feb 20, 2024 - Abstract #AAD2024AAD_2924;
This analysis highlighted the short- and long-term effectiveness and durability of anti-IL-17A/RA biologics compared to other biologic classes. Kaplan
- Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Tremfya (guselkumab) / J&J
Factor Analysis of Patient-Reported Adherence with Risankizumab and Guselkumab in the Treatment of Psoriasis and Psoriatic Arthritis () - Feb 20, 2024 - Abstract #AAD2024AAD_2901;
There were no intra-drug differences in satisfaction or adherence despite variations in dosing regimens. Factor loading revealed medication planning, medication administration, and side effects as the top three variables responsible for satisfaction variance between groups.
- A Secret Shopper Assesssment of Psoriasis Drug Manufacturer Assistance Programs Reveals Widely Variable Enrollment Rates and Communication Challenges Across Enrollment Plans (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_2899;
Applications were submitted for PDMAPs associated with risankizumab-rzaa, adalimumab, ixekizumab, guselkumab, secukinumab, apremilast, tildrakizumab-asmn, and brodalumab. There are significant timeliness and enrollment differences across PDMAPs.
- Tremfya (guselkumab) / J&J
VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_2890;
There are significant timeliness and enrollment differences across PDMAPs. After 3 doses, 80% of participants with at least mild scalp psoriasis achieved clear or almost clear scalp psoriasis with GUS, and reported significant improvements in scalp itch.
- Tremfya (guselkumab) / J&J
GUIDE trial results after withdrawal in part 3: Long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms () - Feb 20, 2024 - Abstract #AAD2024AAD_2879;
After 3 doses, 80% of participants with at least mild scalp psoriasis achieved clear or almost clear scalp psoriasis with GUS, and reported significant improvements in scalp itch. Conclusions After treatment withdrawal, SRes treated with guselkumab within <15m from symptom onset had a longer treatment-free time and were more likely to have clear skin than SRes treated within 15
- Tremfya (guselkumab) / J&J
GUIDE trial (part 3): Following guselkumab withdrawal and a long treatment-free period, disease control is rapidly regained upon re-treatment in psoriasis super-responders () - Feb 20, 2024 - Abstract #AAD2024AAD_2877;
Conclusions Following guselkumab withdrawal, SRes generally had a long treatment-free period. Those who subsequently lost response quickly regained disease control, mostly within 8 weeks after just one guselkumab dose, with no differences between subgroups.
- Biologic efficacy and reasons for discontinuation in a tertiary referral hidradenitis suppurativa clinic (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2364;
Infliximab discontinuation rates were the lowest among the TNF-alpha inhibitors. Rates of discontinuation of second-line therapies are high, emphasizing the urgent need to develop effective treatments for refractory HS.
- Dermatology Medications with the Highest Cost Burden on Medicare Part D: Potential Implications of the Inflation Reduction Act () - Feb 20, 2024 - Abstract #AAD2024AAD_2120;
In this study, we identify dermatology medications with highest cost burden and most significant pricing changes, criteria that will be evaluated under the Inflation Reduction Act. This information may guide Part D benefit design, formulary restructuring, and insurer negotiations to benefit Medicare beneficiaries.
- | Journal: Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort. (Pubmed Central) - Feb 19, 2024
The multi-failure patient is characterized by many comorbidities and longstanding inflammatory disease that frequently precedes the introduction of systemic biologic therapy. Further studies are needed to identify more specific criteria that could be applied as a guideline by clinicians.
- | Tremfya (guselkumab) / J&J
Preclinical, Journal: A Novel human IL-23A Overexpressing Mouse Model of Systemic Lupus Erythematosus. (Pubmed Central) - Feb 16, 2024
We have generated and characterized a novel genetic mouse model of SLE, providing proof-of-concept for the etiopathogenic role of hIL-23A. This new model has a normal lifespan and integrates several characteristics of the human disease's complexity and chronicity making it an attractive preclinical tool for studying IL23-dependent pathogenic mechanisms and assessing the efficacy of anti-hIL23A or modeled disease-related therapeutics.
- |||||||| Tremfya (guselkumab) / J&J
New P3 trial: QUASAR Jr: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Feb 15, 2024
P3, N=120, Recruiting, Sponsor: Janssen Research & Development, LLC
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J
Journal: Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor). (Pubmed Central) - Feb 9, 2024
P4
This new model has a normal lifespan and integrates several characteristics of the human disease's complexity and chronicity making it an attractive preclinical tool for studying IL23-dependent pathogenic mechanisms and assessing the efficacy of anti-hIL23A or modeled disease-related therapeutics. As compared to GUS, IXE provided a faster skin clearance and more days with clear skin in all body regions of patients with moderate-to-severe plaque PsO through 24 weeks.
- | Tremfya (guselkumab) / J&J
Journal: Rapid resolution of guttate psoriasis without recurrence for one?year following two doses of guselkumab. (Pubmed Central) - Feb 2, 2024
As compared to GUS, IXE provided a faster skin clearance and more days with clear skin in all body regions of patients with moderate-to-severe plaque PsO through 24 weeks. No abstract available